



Attorney Docket No. 9233-62

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Ekwuribe et al.
Serial No.: 09/873,757

Confirmation No.: 2357

Art Unit: 1654

Filed: June 4, 2001

Examiner: J. Russel

For: *Mixtures of Growth Hormone Drug-Oligomer Conjugates Comprising Polyalkylene Glycol, Uses Thereof, and Methods of Making Same*

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

January 13, 2004

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Attached is a list of documents on Form PTO-1449, along with a copy of each listed document. It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP.

Also attached is a Declaration of James Gordon Still under 37 C.F.R. § 1.132 (originally prepared for submission in application serial no. 10/075,097) in which Dr. Still provides information about the slides that are included on the attached PTO Form 1449 as items 99 and 103. Although applicants provide these slides to the examiner in the interest of full disclosure in accordance with applicant's duty, it is applicants' belief that these slides are not "printed publications" as set forth in 35 U.S.C. § 102(b) and are thus not prior art to the claimed invention. Applicants base this belief on a comparison of the facts in this case as set forth in Dr. Still's Declaration with the facts set forth in *Regents of the University of California v. Howmedica, Inc.* [210 U.S.P.Q. 727 (D.N.J. 1981); *aff'd*, 676 F.2d 687 (3rd Cir. 1982); copy enclosed], in which the court determined that slides shown during an oral presentation did not constitute a "printed publication" within the meaning of 35 U.S.C. § 102(b). Because the facts reviewed by the court parallel the facts of the present application, applicants believe these slides are not prior art against the invention as claimed in the present application.

This Supplemental Information Disclosure Statement and Form PTO-1449 are submitted in accordance with 37 C.F.R. § 1.97(b)(4), before the mailing of a first Office

In re: Ekwuribe et al.
Serial No.: 09/873,757
Filed: June 4, 2001
Page 2 of 2

Action after the filing of a Request for Continued Examination. Therefore, no fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220

Respectfully submitted,



Shawna Cannon Lemon
Registration No. 53,888

Customer Number 20792

Myers Bigel Sibley & Sajovec, P.A.
P.O. Box 37428
Raleigh, NC 27627
919-854-1400
919-854-1401 (Fax)

CERTIFICATE OF EXPRESS MAILING

Express Mail Label No. EV 381448585 US

Date of Deposit: January 13, 2004

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



Susan E. Freedman

Date of Signature: January 13, 2004

Substitute form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/873,757
				Filing Date	06/04/2001
				First Named Inventor	Nnochiri N. Ekwuribe
				Group Art Unit	1654
				Examiner Name	J. Russel
Sheet	1	of	5	Attorney Docket Number	9233-62


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
	1	EP	0 822 218	A2	Glenn A. Miller et al.	02/04/1998
	2	JP	01207320		Daicel Chem Ind Ltd.	08/21/1989
	3	EP	0 483 465	B1	Salama et al.	08/02/1995
	4	EP	0 511 903	A2	Medgenix Group, S.A.	11/04/1992
	5	DE	196 32 440	A1	BASF AG	02/19/1998
	6	EP	0 031 567	A2	Takeda Yakuhin Kogyo Kabushiki Kaisha	07/08/1981
	7	EP	0 597 007	B1	Smithkline Beecham Corporation	10/16/1996
	8	EP	0 621 777	B1	Alfatec-Pharma GmbH	09/11/1996
	9	EP	0 797 615	B1	The University of Nottingham	01/13/1999
	10	GB	1 492 997		Derek George Smyth	11/13/1977
	11	JP	1 254 699		Kodama Co., Ltd.	10/11/1989
	12	WO	01/12230		Park et al.	02/22/2001
	13	WO	93/01802		Debio Recherche Pharmaceutique, S.A.	02/04/1993
	14	WO	95/09831		Piero Del Soldato et al.	04/13/1995
	15	WO	95/30641		Nicox Limited	11/16/1995
	16	WO	98/07745		Micrologix Biotech, Inc.	02/26/1998
	17	WO	99/65941	A1	King College London et al.	12/23/1999
	18	WO	99/32134		Enzon Inc.	07/01/1999

OTHER NON PATENT LITERATURE DOCUMENTS				T
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
	19	Abuchowski, A. and F. F. Davis "Soluble Polymer-Enzyme Adducts" pp. 367-383, <i>Enzymes as Drugs</i> , Ed. J. S. Holcenberg, John Wiley (1981)		
	20	Agarwal et al. "Polymethacrylate-based Microparticulates of Insulin for Oral Delivery: Preparation and In Vitro Dissolution Stability in the Presence of Enzyme Inhibitors" <i>International Journal of Pharmaceutics</i> 225:31-39 (2001)		
	21	Akiyama et al. "The Synthesis of New Derivatives of 1-β-D-Arabinofuranosylcytosine" <i>Chem. Pharm. Bull.</i> 26(3):981-984 (1978)		
	22	Allaudeen et al. "Orally Active Insulin: A Single Insulin Conjugate Selected for Future Studies" 60th Annual Meeting of the American Diabetes Assoc., Atlanta, GA, June 2000 (Abstract)		
	23	Anderson et al. "HIM2, a Novel Modified Insulin, has Improved Systemic Pharmacokinetics in Normal Dogs, Compared to Unmodified Insulin" American Diabetes Association 62nd Annual Meeting, June 2002 (Abstract)		
	24	Ansell et al. "Application of Oligo-(14-amino-3,6,9,12-tetraoxatetradecanoic acid) Lipid Conjugates as Steric Barrier Molecules in Liposomal Formulations" <i>Bioconjugate Chem.</i> 10:653-666 (1999)		
	25	Aoshima et al. "N ⁶ -Behenoyl-1-β-D-Arabinofuranosylcytosine as a Potential New Antitumor Agent" <i>Cancer Research</i> 37:2481-2486 (1977)		
	26	Baker, D. C. et al. "Prodrugs of 9-β-D-Arabinofuranosyladenine. 1. Synthesis and Evaluation of Some 5'-(O-Acyl) Derivatives" <i>J. Med. Chem.</i> 21(12):1218-1221 (1978)		
	27	Banting et al. "Pancreatic Extracts in the Treatment of Diabetes Mellitus: Preliminary Report" <i>Can. Med. Assoc. J.</i> 145(10):1281-1286 (1991)		
	28	Baudys et al. "Stabilization and Intestinal Absorption of Human Calcitonin" <i>J. Contr. Rel.</i> 39:145-51 (1996)		
	29	Baudys et al. "Synthesis and Characterization of Different Glycosylated Derivatives of Insulin" <i>Proceed. Intern. Symp. Cont. Rel. Bioactive. Mater.</i> 19:210-211 (1992)		
	30	Block, Lawrence H. "Pharmaceutical Emulsions and Microemulsions" <i>Pharmaceutical Dosage Forms: Disperse Systems</i> Vol. 2, Ed. Lieberman et al., pp. 47-109 (1996)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute form 1449A/PTO			Compleat if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/873,757	
			Filing Date	06/04/2001	
			First Named Inventor	Nnochiri N. Ekwuribe	
			Group Art Unit	1654	
			Examiner Name	J. Russel	
Sheet	2	of	5	Attorney Docket Number	9233-62

	31	Boccu et al. "Pharmacokinetic Properties of Polyethylene Glycol Derivatized Superoxide Dismutase" <i>Pharm. Res. Comm.</i> 14:113-120 (1982)	
	32	Bone et al. "Successful Treatment of an Insulin Dependent Rat Model of Human Type I Diabetes with Orally Active Insulin" Program and Abstracts, 4th International Workshop on Lessons from Animal Diabetes, Omiya, Japan, November 1994 (Abstract)	
	33	Bone et al. "Successful Treatment of Type 1 Diabetes with Orally-Active Insulin: Studies in The Insulin Dependent BB/S Rat" Program and Abstracts, 55th Annual Meeting of the American Diabetes Association, Atlanta Georgia, June 1995 (Abstract)	
	34	Brange and Volund "Insulin Analogs with Improved Pharmacokinetic Profiles" <i>Advanced Drug Delivery Reviews</i> 35:307-335 (1999)	
	35	Brange et al. "Chemical Stability of Insulin. 1. Hydrolytic Degradation During Storage of Pharmaceutical Preparations" <i>Pharm. Res.</i> 9(6):715-726 (1992)	
	36	Brange et al. "Chemical Stability of Insulin. 2. Formation of Higher Molecular Weight Transformation Products During Storage of Pharmaceutical Preparations" <i>Pharm. Res.</i> 9(6):727-734 (1992)	
	37	Brange, J. "Galenics of Insulin: The Physico-Chemical and Pharmaceutical Aspects of Insulin and Insulin Preparations" Novo Research Institute, Denmark, pp. 18-100 (1987)	
	38	Chien, Y. W., <i>Novel Drug Delivery Systems</i> , pp. 678-679, Marcell Deffer, Inc., New York, N.Y. (1992)	
	39	Cleland et al. "Emerging Protein Delivery Methods" <i>Current Opinion in Biotechnology</i> 12:212-219 (2001)	
	40	Clement et al. "Effects of Multiple Doses of Orally Administered Hexyl Insulin M2 (HIM2) on Postprandial Blood Glucose (PPG) Concentrations in Type 1 Diabetic (T1) Patients" American Diabetes Association 62nd Annual Meeting, June 2002 (Poster)	
	41	Clement et al. "Oral Insulin Product Hexyl-Insulin Monoconjugate 2 (HIM2) in Type 1 Diabetes Mellitus: The Glucose Stabilization Effects of HIM2" <i>Diabetes Technology & Therapeutics</i> 4(4):459-466 (2002)	
	42	Clement, Stephen "A Dose-Escalation Study of the Effects of Two Sequential Doses of Oral Modified Insulin on Blood Glucose Concentrations in Patients with Type 1 Diabetes Mellitus" American Diabetes Association Annual Meeting (June 25, 2001) (Abstract)	
	43	Clement, Stephen "A Dose-Escalation Study of the Effects of Two Sequential Doses of Oral Modified Insulin on Blood Glucose Concentrations in Patients with Type 1 Diabetes Mellitus" American Diabetes Association Annual Meeting (June 25, 2001) (Poster)	
	44	Conradi et al. "The Influence of Peptide Structure on Transport Across Caco-2 Cells" <i>Pharm. Res.</i> 8(12):1453-1459 (1991)	
	45	Coombes et al. "Biodegradable Polymeric Microparticles for Drug Delivery and Vaccine Formulation: the Surface Attachment of Hydrophilic Species Using the Concept of Poly(Ethylene Glycol) Anchoring Segments" <i>Biomaterials</i> 18:1153-1161 (1997)	
	46	Damge et al. "Poly(alkyl cyanoacrylate) Nanospheres for Oral Administration of Insulin" <i>Journal of Pharmaceutical Sciences</i> 86(12):1403-1409 (Dec. 1997)	
47	Dandona et al. "Effect of an Oral Modified Insulin on Blood Glucose Levels in Fasting and Fed Type 1 Diabetic Patients Receiving a 'Basal' Regimen of Injected Insulin" American Diabetes Association Annual Meeting (June 25, 2001) (Abstract)		
48	Delgado et al. "The Uses and Properties of PEG-Linked Proteins" <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> 9(3,4):249-304 (1992)		
49	Ekwuribe, Nnochiri "Conjugation-Stabilized Polypeptide Compositions, Therapeutic Delivery and Diagnostic Formulations Comprising Same, and Method of Making and Using the Same" <i>Biotechnology Advances</i> 14(4):575-576 (1996) (Abstract)		
50	Engel et al. "Insulin: Intestinal Absorption as Water-in-Oil-in-Water Emulsions" <i>Nature</i> 219:856-857 (1968)		
51	Fasano, A. "Innovative strategies for the oral delivery of drugs and peptides" <i>TIBTECH</i> 16:152-157 (1998)		
52	Forst et al. "New Aspects on Biological Activity of C-peptide in IDDM Patients" <i>Exp. Clin. Endocrinol. Diabetes</i> 106:270-276 (1998)		
53	Francis et al. "Polyethylene Glycol Modification: Relevance of Improved Methodology to Tumour Targeting" <i>Journal of Drug Targeting</i> 3:321-340 (1996)		
54	Gish et al. "Nucleic Acids. 11. Synthesis of 5'-Esters of 1-β-D-Arabinofuranosylcytosine Possessing Antileukemic and Immunosuppressive Activity" <i>J. Med. Chem.</i> 14(12):1159-1162 (1971)		
55	Gombotz & Petit "Biodegradable Polymers for Protein and Peptide Drug Delivery" <i>Bioconjugate Chem.</i> 6:332-351 (1995)		
56	Guzman et al. "Effects of Fatty Ethers and Stearic Acid on the Gastrointestinal Absorption of Insulin" <i>PRHSJ</i> 9(2):155-159 (1990)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/873,757
				Filing Date	06/04/2001
				First Named Inventor	Nnochiri N. Ekwuribe
				Group Art Unit	1654
				Examiner Name	J. Russel
Sheet	3	of	5	Attorney Docket Number	9233-62

57	Hashimoto et al. "Synthesis of Palmitoyl Derivatives of Insulin and Their Biological Activities" <i>Pharmaceutical Research</i> 6(2):171-176 (1989)
58	Hinds et al. "Synthesis and Characterization of Poly(ethylene glycol)-Insulin Conjugates" <i>Bioconjugate Chem.</i> 11:195-201 (2000)
59	Hong et al. "Nucleoside Conjugates. 7. Synthesis and Antitumor Activity of 1-β-D-Arabinofuranosylcytosine Conjugates of Ether Lipids" <i>J. Med. Chem.</i> 29:2038-2044 (1986)
60	Hostettler et al. "Synthesis and Antiretroviral Activity of Phospholipid Analogs of Azidothymidine and Other Antiviral Nucleosides" <i>The Journal of Biological Chemistry</i> 265(11):6112-6117 (1990)
61	Igarashi et al. "Biologically Active Peptides Conjugated with Lecithin for DDS" <i>Proceed. Intern. Symp. Cont. Rel. Bioactiv. Mater.</i> 17:367-368 (1990)
62	Kemmler et al. "On the Nature and Subcellular Localization of the Proinsulin Converting Enzymes" <i>Federation Proceedings</i> 30(Abstract 924):1210Abs (1971)
63	Kemmler et al. "Studies on the Conversion of Proinsulin to Insulin: I. Conversion in Vitro with Trypsin and Carboxypeptidase B" <i>The Journal of Biological Chemistry</i> 246(22):6786-6791 (1971)
64	King et al. "Preparation of Protein Conjugates with Alkoxypolyethylene Glycols" <i>Int. J. Peptide Protein Res.</i> 16:147-155 (1980)
65	Kipnes et al. "Control of Postprandial Plasma Glucose by an Oral Insulin Product (HIM2) in Patients with Type 2 Diabetes" <i>Emerging Treatments and Technologies</i> 26:2 (2003)
66	Kipnes et al. "The Effects of an Oral Modified Insulin on Postprandial Blood Glucose Levels in Patients with Type 2 Diabetes" American Diabetes Association Annual Meeting (June 24, 2001) (Abstract)
67	Kipnes et al. "The Effects of an Oral Modified Insulin on Postprandial Blood Glucose Levels in Patients with Type 2 Diabetes Mellitus" American Diabetes Association Annual Meeting (June 2001) (Poster)
68	Krishnan, B. Radha, et al., "Stability and Physical Characteristics of Orally Active Amphiphilic Human Insulin Analog, Methoxy (Polyethylene Glycol) Hexanoyl Human Recombinant Insulin (HIM2)", <i>Proceed. Int'l. Symp. Control. Rel. Bioact. Mater.</i> , 27:1038-1039 (2000)
69	Kube, D.M. "Multitalented Proteins Play a Key Role in Therapeutics" <i>Genomics and Proteomics</i> (Sept. 2002)
70	Lindsay et al. <i>The Acetylation of Insulin Biochem J.</i> 121:737-745 (1971)
71	Maislos et al. "The Source of the Circulating Aggregate of Insulin in Type I Diabetic Patients is Therapeutic Insulin" <i>J. Clin. Invest.</i> 77:717-723 (1986)
72	M. Savva & L. Huang, "Effect of PEG Homopolymer and Grafted Amphiphilic PEG-Palmityl on the Thermotropic Phase Behavior of 1,2-Dipalmitoyl-SN-Glycero-3-Phosphocholine Bilayer," <i>Journal of Liposome Research</i> , 9(3):357-365 (1999).
73	Marschutz et al. "Oral Peptide Drug Delivery: Polymer-Inhibitor Conjugates Protecting Insulin from Enzymatic Degradation In Vitro" <i>Biomaterials</i> 21:1499-1507 (2000)
74	Mesiha et al. "Hypoglycaemic effect of oral insulin preparations containing Brij 35, 52, 58 or 92 and stearic acid" <i>J. Pharm. Pharmacol.</i> 33:733-734 (1981)
75	Moghaddam, Amir "Use of polyethylene glycol polymers for bioconjugations and drug development" <i>American Biotechnology Laboratory</i> pp. 42, 44 (July 2001)
76	Musabayane et al. "Orally Administered, Insulin-Loaded Amidated Pectin Hydrogel Beads Sustain Plasma Concentrations of Insulin in Streptozotocin-Diabetic Rats" <i>Journal of Endocrinology</i> 164:1-6 (2000)
77	Neubauer et al. "Influence of Polyethylene Glycol Insulin on Lipid Tissues of Experimental Animals" <i>Diabetes</i> 32:953-958 (October 1983)
78	Nucci et al. "The Therapeutic Value of Poly(ethylene Glycol)--Modified Proteins" <i>Ad. Drug. Del. Rev.</i> 6:133-151 (1991)
79	Oka et al. "Enhanced Intestinal Absorption of a Hydrophobic Polymer-Conjugated Protein Drug, Smancs, in an Oily Formulation" <i>Pharm. Res.</i> 7(8):852-855 (1990)
80	Pang, David C. "Bridging Gaps in Drug Discovery and Development" <i>Pharmaceutical Technology</i> 22:82-94 (Nov. 1998)
81	Patel et al. "Oral Administration of Insulin By Encapsulation Within Liposomes" <i>FEBS Lett.</i> 62(1):60-63 (1976)
82	Price, JC <i>Polyethylene Glycol</i> , pp. 355-361
83	Puskas et al. "Investigation of Chymotrypsin Digestion Profile of Orally Active Insulin Conjugate HIM2" <i>AAPS Pharm Sci.</i> 3(3) 2001 (Abstract)
84	Radhakrishnan et al. "Chemical Modification of Insulin with Amphiphilic Polymers Improves Intestinal Delivery," <i>Proceed. Intl. Symp. Control. Rel. Bioact. Mater.</i> 25:124-125 (1998) (Abstract)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/873,757
				Filing Date	06/04/2001
				First Named Inventor	Nnochiri N. Ekwuribe
				Group Art Unit	1654
				Examiner Name	J. Russel
Sheet	4	of	5	Attorney Docket Number	9233-62

85	Radhakrishnan et al. "Oral Delivery of Insulin: Single Selective Modification at B29-LYS With Amphiphilic Oligomer" Program and Abstracts, 1999 National Meeting of the Ameri. Assoc. Pharm. Scient., New Orleans, LA (1999) (Abstract)
86	Radhakrishnan et al. "Structure-Activity Relationship of Insulin Modified with Amphiphilic Polymers" Program and Abstracts, 1998 National Meeting of the Amer. Assoc. Pharm. Scient., San Francisco, CA Pharm. Sci. 1(1):S-59 (1998) (Abstract)
87	Ratner, R. E. et al. "Persistent Cutaneous Insulin Allergy Resulting from High-Molecular Weight Insulin Aggregates" <i>Diabetes</i> 39:728-733 (1990)
88	Richards et al. "Self-Association Properties of Monomeric Insulin Analogs Under Formulation Conditions" <i>Pharmaceutical Research</i> 15(9):1434-1441 (1998)
89	Robbins et al. "Antibodies to Covalent Aggregates of Insulin in Blood of Insulin-Using Diabetic Patients" <i>Diabetes</i> 36:838-841 (1987)
90	Russell-Jones, G. J. "Vitamin B12 Drug Delivery" <i>Proceed. Intern. Symp. Control. Rel. Bioactive. Mater.</i> 19:102-103 (1992)
91	Saffran et al. "A Model for the Study of the Oral Administration of Peptide Hormones" <i>Can J Biochem</i> 57:548-553 (1979)
92	Saffran, M. et al. "A New Approach to the Oral Administration of Insulin and Other Peptide Drugs" <i>Science</i> 233:1081-1084 (1986)
93	Santiago et al. "Oral Immunization of Rats with Influenza Virus M Protein (M1) Microspheres" <i>Proceed. Intern. Symp. Cont. Rel. Bioactive. Mater.</i> 19:116-117 (1992)
94	Shah and Shen "Transcellular Delivery of an Insulin-Transferrin Conjugate in Enterocyte-like Caco-2 Cells" <i>Journal of Pharmaceutical Sciences</i> 85(12):1306-1311 (1996)
95	Shen et al. "(C) Means to Enhance Penetration; (3) Enhancement of polypeptide and protein absorption by macromolecular carriers via endocytosis and transcytosis" <i>Advanced Drug Del. Reviews</i> 8:93-113 (1992)
96	Shichiri et al. "Enteral Absorption of Water-in-Oil-in-Water Insulin Emulsions in Rabbits" <i>Diabetologia</i> 10:317-321 (1974)
97	Sirokman et al. "Refolding and proton pumping activity of a polyethylene glycol-bacteriorhodopsin water-soluble conjugate" <i>Protein Science</i> 12:1161-1170 (1993)
98	Still and McAllister "Effects of Orally Active Modified Insulin in Type 1 Diabetic Patients" <i>Clinical Pharmacol. Therap.</i> 69(2):P95 (Feb. 2001) (Abstract)
99	Still and McAllister "Effects of Orally Active Modified Insulin in Type I Diabetic Patients" Slide Presentation Annual Meeting of the American Society for Clinical Pharmacology & Therapeutics, Orlando, FL, March 9, 2001
100	Still and McAllister "Effects of Orally Active Modified Insulin in Type I Diabetic Patients" Annual Meeting of the American Society for Clinical Pharmacology & Therapeutics, Orlando, FL, March 9, 2001 (Handout)
101	Still et al. "Magnitude and Variability of Pharmacokinetic and Glucodynamic Responses to Modified Human Insulin Administered Orally to Healthy Volunteers" <i>Diabetes Research and Clinical Practice</i> 56:S77 (2002)
102	Still, J. Gordon "Development of Oral Insulin: Progress and Current Status" <i>Diabetes/Metabolism Research and Reviews</i> 18(1):S29-S37 (2002)
103	Still, J. Gordon "Oral Insulin Development" Slide Presentation, VI International St. Barts Symposium Diabetes 2000: Therapy and Technology, London, England, May 12, 2000
104	Szleifer et al. "Spontaneous Liposome Formation Induced by Grafted Poly(Ethylene Oxide) Layers: Theoretical Prediction and Experimental Verification" <i>Proceedings of the National Academy of Sciences of the United States of America</i> 95(3):1032-1037 (1998)
105	Taniguchi et al. "Synthesis of Acyloyl Lysozyme and Improvement of its Lymphatic Transport Following Small Intestinal Administration in Rats" <i>Proceed. Intern. Symp. Control. Rel. Bioactiv. Mater.</i> 19:104-105 (1992)
106	Torchilin, Vladimir P. "Immunoliposomes and PEGylated Immunoliposomes: Possible Use for Targeted Delivery of Imaging Agents" <i>Immunomethods</i> 4:244-258 (1994)
107	Uchio et al. "Site-Specific Insulin Conjugates with Enhanced Stability and Extended Action Profile" <i>Advanced Drug Delivery Reviews</i> 35:289-306 (1999)
108	Vreeland et al. "Molar Mass Profiling of Synthetic Polymers by Free-Solution Capillary Electrophoresis of DNA-Polymer Conjugates" <i>Analytical Chemistry</i> 73(8):1795-1803 (2001)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	5	of	5
-------	---	----	---

Sheet	5	of	5
-------	---	----	---

Application Number	09/873,757
Filing Date	06/04/2001
First Named Inventor	Nnochiri N. Ekwuribe
Group Art Unit	1654
Examiner Name	J. Russel
Attorney Docket Number	9233-62

Application Number	09/873,757
Filing Date	06/04/2001
First Named Inventor	Nnochiri N. Ekwuribe
Group Art Unit	1654
Examiner Name	J. Russel
Attorney Docket Number	9233-62

[illegible]

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.